Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

Betriú, Carmen; Redondo, Montserrat; Boloix, Ana; Gómez, Manuel; Culebras, Esther; Picazo, Juan J.

doi:10.1093/jac/48.6.911

Cited by 37 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on these results, daptomycine appears to be a good therapy option for infections caused by these bacteria. Similarly, in a study by Betriu et al (2001), linezolid was found to be potentially useful in the treatment of infections caused by MRSA and for MRCNS strains that have decreased sensitivity to teicoplanin [3].…”

Section: Discussionmentioning

confidence: 94%

Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics

Öksüz

Gürler

2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Background: The treatment of methicillin-resistant staphylococcal infections has been a growing problem both in and out of hospitals for the past 30 years. Therefore, there is a need for other antibiotics as an alternative to glycopeptides in the treatment of methicillin-resistant staphylococcal infections. This study investigated the in vitro susceptibility of 49 methicillin-resistant Staphylococcus aureus (MRSA) and 59 methicillin-resistant coagulase negative staphylococci (MRCNS) clinical isolates to daptomiycin, telithromycin, tigecyclin, quinupristin/dalfopristin, and linezolid. Methodology: The identification of the strains was made by conventional methods. Antibiotic susceptibility tests were performed according to CLSI. Methicillin resistance was determined by cefoxitin disk. Susceptibilities of the strains to daptomycin, quinupristin/dalfopristin, tigecycline, and vancomycin were performed using the E-test according to the recommendations of CLSI 2011 and the manufacturer. Results: Two strains of MRCNS were resistant, and one was teicoplanin intermediate. It was found that one (2%) strain of MRSA and two (3%) strains of MRCNS were resistant to tigecyclin. Telithromycin resistance was detected in 33% of MRSA strains and 37% of MRCNS strains. Inducible clindamycin resistance was found in nine (18.4%) strains of MRSA and eighteen (30.5%) strains of MRCNS. All strains were susceptible to daptomiycin, quinupristin/dalfopristin, and linezolid. Conclusions:Although it has recently been used, telithromycin has a high percentage of resistance; its use for methicillin-resistant staphylococcal strains, therefore, should be limited. Daptomycin and quinupristin/dalfopristin were found to be effective against MRSA and MRCNS strains and were concluded to be a good choice in the treatment of methicillin-resistant staphylococci.

show abstract

Section: Discussionmentioning

confidence: 94%

Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics

Öksüz

Gürler

2013

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Multiple in vitro and in vivo studies have demonstrated that linezolid is either more potent or as active in the eradication of Gram-positive cocci when compared with traditional antimicrobial agents such as vancomycin or other novel antibiotics, eg, quinupristin-dalfopristin (27)(28)(29). The causes for its superior efficacy compared to vancomycin are yet to be determined.…”

Section: Discussionmentioning

confidence: 99%

“…The causes for its superior efficacy compared to vancomycin are yet to be determined. Both vancomycin and linezolid have similar halflives of 6 to 8 h (21,(29)(30) and postantibiotic effects of 1 to 2 h (31,32). Vancomycin has lower minimum inhibitory concentrations for many Gram-positive cocci compared with linezolid.…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin‐Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment

Schwalm

El‐Helou

Lee

2004

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Drug-resistant Gram-positive bacteria, especially Staphylococcus aureus, are emerging as the predominant organisms involved in both nosocomial and community-acquired infections. Since the 1980s, vancomycin has been the first-line antibiotic used to treat methicillin-resistant S aureus. However, allergy and intolerance to vancomycin, the increasing number of vancomycin clinical failures and the existence of vancomycin intermediate-susceptible isolates of S aureus suggest that new antibiotics are needed. This paper reports the only known case of a successful clinical outcome with long term oral linezolid and rifampin therapy in the management of recurrent and persistent methicillin-resistant S aureus bacteremia with metastatic infections despite prolonged vancomycin use. More than two years since the initiation of linezolid and rifampin, the study patient has been clinically well with no evidence of adverse drug reactions including cytopenia and hepatic toxicities. Physicians must be aware of the novel developments in antibiotic therapy to treat drug-resistant bacterial infections.

show abstract

“…10 In vitro, linezolid, quinupristin-dalfopristin, moxifloxacin and trovafloxacin, which are new antibiotics, reveal good activity against MRSA and methicillin-resistant and teicoplaninintermediate coagulase negative staphylococci. 11 In particular, linezolid has an acceptable safety profile for both i.v. and oral administration and has proven effective in the treatment of infections caused by methicillin-resistant staphylococcal species in critically ill patients.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intrathecal vancomycin in an allogeneic peripheral blood stem cell transplant recipient

Matsubara

Makimoto

Higa

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Methicillin-resistant Staphylococcus aureus (MRSA) is a common infectious pathogen during stem cell transplantation. We report a case of meningoencephalitis with multiple abscess formation caused by MRSA, which occurred in a 4-year-old boy soon after allogeneic peripheral blood stem cell transplantation. We successfully cured the infection with a combination of intravenous and intrathecal vancomycin.

show abstract

Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

Cited by 37 publications

References 8 publications

Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics

Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics

Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin‐Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment

Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intrathecal vancomycin in an allogeneic peripheral blood stem cell transplant recipient

Contact Info

Product

Resources

About